Martin Shkreli Convicted of Fraud by U.S. Jury in New York

Martin Shkreli, once dubbed “the most hated man in America,” is now a convicted felon.

Shkreli, notorious for raising the price of a potentially life-saving drug by 5,000 percent, was found guilty Friday of defrauding investors in two hedge funds and in Retrophin Inc., a pharmaceutical company he co-founded.

He is now almost certain to go to prison. Shkreli faces as long as 20 years behind bars, although he’s likely to serve much less. U.S. District Judge Kiyo Matsumoto allowed him to return home and wished Shkreli well after the verdict was read. She said she would see him soon, though she hasn’t set a date for sentencing.

In the end, it was Shkreli’s lies to his investors that cost him his freedom, not his 2015 decision to jack up the price of an anti-parasitic drug. Prosecutors said Shkreli, 34, misled clients about the performance of his failing hedge funds, secretly used their money to start Retrophin, and then took $11 million from the drug-development company to repay them.

Shkreli was convicted of three of eight charges, including securities fraud.

The verdict came on the fifth day of deliberations after a trial that sometimes resembled a circus. Shkreli’s notoriety for boosting the price of Daraprim made jury selection a time-consuming process as dozens of prospective jurors expressed contempt for him. One called him a “snake,” and another said he was “the face of corporate greed.” Neither was selected for the panel.

Hailed as “Pharma Bro” by his online supporters, Shkreli has won a following for sharing much of his life on the Internet, broadcasting live from his Manhattan apartment. In the evenings after a long day in court, he could be seen chatting with his followers, petting his cat, combing his hair and playing chess. While he was kicked off Twitter for harassing a female journalist, he took to Facebook during the monthlong trial to rail against prosecutors.

Stop Talking

A courthouse tirade got Shkreli reprimanded by the judge. After telling reporters during a lunch break that the prosecutors in Brooklyn were the “junior varsity,” Matsumoto ordered him to stop talking about the case in and around the building.

Prosecutors presented more than a dozen witnesses, including investors who said they had trouble recovering their money from Shkreli and former employees who recounted questionable transactions. A former compliance officer said he got so tired of his boss’s antics that he quit and complained to the U.S. Securities and Exchange Commission.

The government painted Shkreli as a conman and habitual liar. They said his deceit involved not only the performance of his funds and how he used investor money, but his educational background and prior investing experience. Jurors were shown what prosecutors said were sham consulting agreements that Shkreli drafted as part of one of his many schemes to pay back some investors.

Prosecutors said Shkreli boasted to potential hedge fund clients that he was managing as much as $100 million when the net value of one of his funds fell to minus 33 cents, and never held more than $3 million.

Eccentric Genius

Shkreli chose not to testify and his lawyers called no witnesses. His attorneys sought to prove their case through cross-examination of government witnesses, claiming that Shkreli was an eccentric genius whose investors ultimately made millions of dollars — even if it took them years to recover their money.

“This is not a case where anybody was defrauded,” defense attorney Benjamin Brafman said in his closing argument to jurors.

As a teenager living in Brooklyn, Shkreli was an intern at a hedge fund operated by Jim Cramer before working as an analyst at several funds and then starting his own, Elea Capital Management, in 2005 at the age of 23. After Elea collapsed due to bad trades, Shkreli began two other funds, MSMB Capital Management and MSMB Healthcare, and then co-founded Retrophin in 2011.

Shkreli was ousted by Retrophin in 2014 and arrested in December 2015. At another company he founded, Turing Pharmaceuticals LLC, Shkreli raised the price of Daraprim, an AIDS and HIV drug. Criticized harshly, he defended his decision and said he’d do it again.

The case is U.S. v. Shkreli, 15-cr-00637, U.S. District Court, Eastern District of New York (Brooklyn).

Source link